Emma Ruth Miller1, Peng Bi, Philip Ryan. 1. Discipline of Public Health, University of Adelaide, Adelaide, South Australia. emma.miller@deakin.edu.au
Abstract
OBJECTIVES: To determine entry antibody seroprevalence and seroconversion to hepatitis C virus (HCV) and associated risk factors in newly incarcerated prisoners. METHODS: Males and females entering South Australian prisons completed risk factor surveys and were offered HCV-antibody testing. Participants completed additional surveys and, if HCV-negative at last test, underwent further antibody tests at 3-monthly intervals for up to 15 months. Data were analyzed using univariate and multivariate techniques. RESULTS: HCV seroprevalence among 662 prison entrants was estimated at 42%. Previous injecting history was highly prevalent at entry (64%) and both community and prison injecting independently predicted entry HCV status. Tattooing was not an important risk factor. While community exposure could not be ruled out, three seroconversions were noted in 148 initially HCV-seronegative individuals occurring in a median 121 days--4.6 per 100 person-years. Prison injecting was infrequently reported, but HCV-seropositive participants were significantly more likely to commence IDU in prison than seronegative participants (p=0.035). CONCLUSIONS: Entry HCV seroprevalence in South Australian prisoners is extremely high and may have contributed to a 'ceiling effect', minimizing the observable seroconversion rate. Greater frequency of injecting among those already infected with HCV represents a significant threat to other prisoners and prison staff.
OBJECTIVES: To determine entry antibody seroprevalence and seroconversion to hepatitis C virus (HCV) and associated risk factors in newly incarcerated prisoners. METHODS: Males and females entering South Australian prisons completed risk factor surveys and were offered HCV-antibody testing. Participants completed additional surveys and, if HCV-negative at last test, underwent further antibody tests at 3-monthly intervals for up to 15 months. Data were analyzed using univariate and multivariate techniques. RESULTS:HCV seroprevalence among 662 prison entrants was estimated at 42%. Previous injecting history was highly prevalent at entry (64%) and both community and prison injecting independently predicted entry HCV status. Tattooing was not an important risk factor. While community exposure could not be ruled out, three seroconversions were noted in 148 initially HCV-seronegative individuals occurring in a median 121 days--4.6 per 100 person-years. Prison injecting was infrequently reported, but HCV-seropositive participants were significantly more likely to commence IDU in prison than seronegative participants (p=0.035). CONCLUSIONS: Entry HCV seroprevalence in South Australian prisoners is extremely high and may have contributed to a 'ceiling effect', minimizing the observable seroconversion rate. Greater frequency of injecting among those already infected with HCV represents a significant threat to other prisoners and prison staff.
Authors: Suzy Teutsch; Fabio Luciani; Nicolas Scheuer; Luke McCredie; Parastu Hosseiny; William Rawlinson; John Kaldor; Gregory J Dore; Kate Dolan; Rosemary Ffrench; Andrew Lloyd; Paul Haber; Michael Levy Journal: BMC Public Health Date: 2010-10-22 Impact factor: 3.295
Authors: Richard P Sullivan; Rob Baird; Kevin Freeman; Hugh Heggie; Joshua S Davis; Catherine S Marshall; Jane Davies Journal: BMC Infect Dis Date: 2021-06-16 Impact factor: 3.090
Authors: Natasha K Martin; Matthew Hickman; Alec Miners; Sharon J Hutchinson; Avril Taylor; Peter Vickerman Journal: BMJ Open Date: 2013-08-13 Impact factor: 2.692